RTP Mobile Logo
Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Hematologic Cancers — Hodgkin and Non-Hodgkin Lymphoma (Faculty Presentations)
Released December 2020

Featuring slide presentations and related discussion from Drs Jonathan W Friedberg, John Kuruvilla, Ann S LaCasce, John P Leonard and Michael E Williams. (Video Program)

CE Disclosures and Faculty Information


    This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of Hodgkin and non-Hodgkin lymphoma.


    • Consider age, performance status and other clinical and biologic factors in the selection of up-front and subsequent therapy for patients with diffuse large B-cell lymphoma (DLBCL).
    • Recall published research data and other clinical factors in the best-practice selection, sequencing or combination of available therapeutic agents and strategies in the care of patients with previously untreated or relapsed/refractory (R/R) follicular lymphoma (FL).
    • Recognize the mechanisms of action, efficacy and safety of approved and investigational agents for the treatment of newly diagnosed and R/R mantle cell lymphoma (MCL) to determine current and potential utility in clinical practice.
    • Incorporate new therapeutic agents and strategies into the best-practice management of newly diagnosed and R/R Hodgkin lymphoma (HL).
    • Develop an understanding of the biologic rationale for and appreciate the available efficacy and safety data with chimeric antigen receptor T-cell therapy, and identify patients with R/R B-cell lymphomas for whom this approach may be appropriate.
    • Design a plan of care to recognize and manage side effects and toxicities associated with current and recently approved systemic therapies in the management of FL, MCL, HL and DLBCL to support quality of life and continuation of therapy.
    • Recall new data with investigational agents and strategies demonstrating promising activity in various lymphoma subtypes, and discuss clinical trial opportunities with eligible patients.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Research To Practice designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ASHLymphoma20/Presentations/CME.

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Jonathan W Friedberg, MD, MMSc
    Samuel E Durand Professor of Medicine
    Director, James P Wilmot Cancer Institute
    University of Rochester
    Rochester, New York

    Data and Safety Monitoring Board/Committee: Acerta Pharma — A member of the AstraZeneca Group, Bayer HealthCare Pharmaceuticals.

    John Kuruvilla, MD
    Hematologist, Princess Margaret Cancer Centre
    Associate Professor, University of Toronto
    Toronto, Ontario, Canada

    Consulting Agreements: AbbVie Inc, Bristol-Myers Squibb Company, Gilead Sciences Inc, Karyopharm Therapeutics, Merck, Roche Laboratories Inc, Seagen Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Gilead Sciences Inc, Janssen Biotech Inc, Karyopharm Therapeutics, Merck, Novartis, Roche Laboratories Inc, Seagen Inc; Honoraria: Amgen Inc, Antengene, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Gilead Sciences Inc, Janssen Biotech Inc, Karyopharm Therapeutics, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc, Seagen Inc, TG Therapeutics Inc.

    Ann S LaCasce, MD, MMSc
    Director, Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology
    Associate Professor of Medicine, Harvard Medical School
    Lymphoma Program
    Dana Farber Cancer Institute
    Boston, Massachusetts

    Data and Safety Monitoring Board/Committee: Bristol-Myers Squibb Company.

    John P Leonard, MD
    Richard T Silver Distinguished Professor of Hematology and Medical Oncology
    Associate Dean for Clinical Research
    Executive Vice Chair, Joan and Sanford I Weill Department of Medicine
    Weill Cornell Medicine
    New York, New York

    Consulting Agreements: ADC Therapeutics SA, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene, Celgene Corporation, Genentech, a member of the Roche Group, Gilead Sciences Inc, Karyopharm Therapeutics, MEI Pharma Inc, MorphoSys, Nordic Nanovector, Novartis, Roche Laboratories Inc, Sutro Biopharma; Data and Safety Monitoring Board/Committee: Biotest Pharmaceuticals Corporation, Bristol-Myers Squibb Company.

    Michael E Williams, MD, ScM
    Byrd S Leavell Professor of Medicine
    Chief, Hematology/Oncology Division
    Physician Lead, Cancer Service Line
    University of Virginia School of Medicine
    Charlottesville, Virginia

    Advisory Committee: AbbVie Inc; Consulting Agreements: Celgene Corporation, Gilead Sciences Inc, TG Therapeutics Inc; Contracted Research: Allos Therapeutics, Celgene Corporation, Gilead Sciences Inc, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc; Speakers Bureau: Xian Janssen Pharmaceutical Ltd.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Incyte Corporation, Karyopharm Therapeutics and Seagen Inc.

    Release date: January 2021
    Expiration date: January 2022

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):